Zimberelimab

Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma[1][2].

Product Specifications

CAS Number

[2259860-24-5]

Product Name Alternative

GLS-010; AB-122; WBP-3055

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zimberelimab.html

Purity

99.90

Solubility

H2O

Smiles

[Zimberelimab]

Molecular Weight

(144.41 kDa)

References & Citations

[1]Lou B, et al. Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer. Front Oncol. 2021 Sep 15;11:736955.|[2]Markham A. Zimberelimab: First Approval. Drugs. 2021 Nov;81 (17) :2063-2068.